-
公开(公告)号：US09617224B2
公开(公告)日：2017-04-11
申请号：US14722434
申请日：2015-05-27
发明人： Jon J. Hangeland , Mimi L. Quan , Joanne M. Smallheer , Gregory S. Bisacchi , James R. Corte , Todd J. Friends , Zhong Sun , Karen A. Rossi , Cullen L. Cavallaro
IPC分类号： C07D249/08 , C07D249/12 , C07D233/64 , C07D235/16 , C07D231/12 , C07D233/68 , C07D263/14 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D235/08 , C07D263/32 , C07D263/12
CPC分类号： C07D417/14 , C07D231/12 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/08 , C07D235/14 , C07D235/16 , C07D249/08 , C07D249/12 , C07D263/12 , C07D263/14 , C07D263/32 , C07D277/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/06
摘要： The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
-
公开(公告)号：US10112936B2
公开(公告)日：2018-10-30
申请号：US15440346
申请日：2017-02-23
发明人： Jon J. Hangeland , Mimi L. Quan , Joanne M. Smallheer , Gregory S. Bisacchi , James R. Corte , Todd J. Friends , Zhong Sun , Karen A. Rossi , Cullen L. Cavallaro
IPC分类号： C07D263/32 , C07D417/14 , C07D235/16 , C07D231/12 , C07D233/64 , C07D233/68 , C07D249/08 , C07D249/12 , C07D263/14 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D235/08 , C07D263/12 , C07D233/90 , C07D235/14 , C07D277/30 , C07D401/10 , C07D413/10
摘要： The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
-
公开(公告)号：US20170166560A1
公开(公告)日：2017-06-15
申请号：US15440346
申请日：2017-02-23
发明人： Jon J. Hangeland , Mimi L. Quan , Joanne M. Smallheer , Gregory S. Bisacchi , James R. Corte , Todd J. Friends , Zhong Sun , Karen A. Rossi , Cullen L. Cavallaro
IPC分类号： C07D417/14 , C07D233/68 , C07D403/04 , C07D233/90 , C07D405/14 , C07D403/14 , C07D401/14 , C07D401/12 , C07D403/12 , C07D401/10 , C07D409/14 , C07D401/04 , C07D409/04 , C07D403/10 , C07D413/10 , C07D263/32 , C07D249/08 , C07D231/12 , C07D401/06 , C07D417/04 , C07D413/04 , C07D405/04 , C07D235/14 , C07D277/30 , C07D233/64
CPC分类号： C07D417/14 , C07D231/12 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/08 , C07D235/14 , C07D235/16 , C07D249/08 , C07D249/12 , C07D263/12 , C07D263/14 , C07D263/32 , C07D277/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/06
摘要： The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
-
公开(公告)号：US09079860B2
公开(公告)日：2015-07-14
申请号：US14219311
申请日：2014-03-19
发明人： Jon J. Hangeland , Mimi L. Quan , Joanne M. Smallheer , Gregory S. Bisacchi , James R. Corte , Todd J. Friends , Zhong Sun , Karen A. Rossi , Cullen L. Cavallaro
IPC分类号： C07D403/04 , C07D235/16 , C07D235/08 , C07D231/12 , C07D233/64 , C07D233/68 , C07D249/08 , C07D263/12 , C07D263/14 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D263/32
CPC分类号： C07D417/14 , C07D231/12 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/08 , C07D235/14 , C07D235/16 , C07D249/08 , C07D249/12 , C07D263/12 , C07D263/14 , C07D263/32 , C07D277/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/06
摘要： The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
摘要翻译： 本发明提供了治疗有需要的患者治疗有效量的至少一种式（I）或式（V）化合物或其立体异构体或药学上可接受的盐或溶剂化物的血栓形成或炎性病症的方法： 其中变量A，L，Z，R3，R4，R6，R11，X1，X2和X3如本文所定义。 式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽释放酶。 特别地，它涉及作为选择性因子XIa抑制剂的化合物。 本发明还提供了式I范围内的化合物，涉及包含这些化合物的药物组合物。
-
公开(公告)号：US20150259297A1
公开(公告)日：2015-09-17
申请号：US14722434
申请日：2015-05-27
发明人： Jon J. Hangeland , Mimi L. Quan , Joanne M. Smallheer , Gregory S. Bisacchi , James R. Corte , Todd J. Friends , Zhong Sun , Karen A. Rossi , Cullen L. Cavallaro
IPC分类号： C07D233/64 , C07D263/32 , C07D401/12 , C07D403/04 , C07D417/04
CPC分类号： C07D417/14 , C07D231/12 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/08 , C07D235/14 , C07D235/16 , C07D249/08 , C07D249/12 , C07D263/12 , C07D263/14 , C07D263/32 , C07D277/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/06
摘要： The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
-
6.发明申请公开(公告)号：US20140206706A1
公开(公告)日：2014-07-24
申请号：US14219311
申请日：2014-03-19
发明人： Jon J. Hangeland , Mimi L. Quan , Joanne M. Smallheer , Gregory S. Bisacchi , James R. Corte , Todd J. Friends , Zhong Sun , Karen A. Rossi , Cullen L. Cavallaro
IPC分类号： C07D417/04 , C07D263/32 , C07D231/12 , C07D403/04 , C07D235/08 , C07D233/64 , C07D401/12 , C07D249/08
CPC分类号： C07D417/14 , C07D231/12 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/08 , C07D235/14 , C07D235/16 , C07D249/08 , C07D249/12 , C07D263/12 , C07D263/14 , C07D263/32 , C07D277/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/06
摘要： The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
摘要翻译： 本发明提供了治疗有需要的患者治疗有效量的至少一种式（I）或式（V）化合物或其立体异构体或药学上可接受的盐或溶剂化物的血栓形成或炎性病症的方法： 其中变量A，L，Z，R3，R4，R6，R11，X1，X2和X3如本文所定义。 式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽释放酶。 特别地，它涉及作为选择性因子XIa抑制剂的化合物。 本发明还提供了式I范围内的化合物，涉及包含这些化合物的药物组合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.031 秒)
